170 related articles for article (PubMed ID: 15270584)
1. The impact of technological advances on the evolution of 3D conformal brachytherapy for early prostate cancer.
Nori D; Reddy NM; Vaughan ED; Shemtov MM
Technol Cancer Res Treat; 2004 Aug; 3(4):335-45. PubMed ID: 15270584
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
3. Comparison of real-time intraoperative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy.
Nag S; Shi P; Liu B; Gupta N; Bahnson RR; Wang JZ
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):311-7. PubMed ID: 17996395
[TBL] [Abstract][Full Text] [Related]
4. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.
Lee J; Hobbs RF; Zahurak M; Ng SK; Zhang Z; Burdette EC; DeWeese TL; Song DY
Brachytherapy; 2018; 17(6):858-865. PubMed ID: 30217432
[TBL] [Abstract][Full Text] [Related]
6. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Walbert HL
Radiat Oncol Investig; 1998; 6(4):182-90. PubMed ID: 9727878
[TBL] [Abstract][Full Text] [Related]
7. Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.
Nasser NJ; Cohen GN; Dauer LT; Zelefsky MJ
Brachytherapy; 2016; 15(4):420-425. PubMed ID: 27180125
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
10. Does brachytherapy have a role in the treatment of prostate cancer?
Grimm PD; Blasko JC; Ragde H; Sylvester J; Clarke D
Hematol Oncol Clin North Am; 1996 Jun; 10(3):653-73. PubMed ID: 8773503
[TBL] [Abstract][Full Text] [Related]
11. New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.
Brun T; Bachaud JM; Graff-Cailleaud P; Malavaud B; Portalez D; Popotte C; Aziza R; Lusque A; Filleron T; Ken S
Brachytherapy; 2018; 17(3):544-555. PubMed ID: 29525514
[TBL] [Abstract][Full Text] [Related]
12. Prostate post-implant dosimetry: interobserver variability in seed localisation, contouring and fusion.
De Brabandere M; Hoskin P; Haustermans K; Van den Heuvel F; Siebert FA
Radiother Oncol; 2012 Aug; 104(2):192-8. PubMed ID: 22857857
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
14. A systematic study of imaging uncertainties and their impact on 125I prostate brachytherapy dose evaluation.
Lindsay PE; Van Dyk J; Battista JJ
Med Phys; 2003 Jul; 30(7):1897-908. PubMed ID: 12906208
[TBL] [Abstract][Full Text] [Related]
15. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
16. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy.
Hanania AN; Kudchadker RJ; Bruno TL; Tang C; Anscher MS; Frank SJ
Brachytherapy; 2020; 19(1):38-42. PubMed ID: 31812590
[TBL] [Abstract][Full Text] [Related]
17. Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants.
Acher P; Rhode K; Morris S; Gaya A; Miquel M; Popert R; Tham I; Nichol J; McLeish K; Deehan C; Dasgupta P; Beaney R; Keevil SF
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1518-25. PubMed ID: 18513881
[TBL] [Abstract][Full Text] [Related]
18. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients.
Reed DR; Wallner KE; Narayanan S; Sutlief SG; Ford EC; Cho PS
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):301-7. PubMed ID: 16111600
[TBL] [Abstract][Full Text] [Related]
20. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
